We followed up with additional HER2 immunohistochemistry of 28 RB tumors in different zones (central tumor, transitional zone, leading edge, vitreous seeds) to assess regional differences in HER2 immunoreactivity. The gene discussed is ERBB2; the disease is neoplasm.